Arthneeti
All Q1 FY27 results →
H

Health.Global

Q1 FY27Healthcare Services

Healthcare Global Enterprises Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Price₹720
Market cap₹10.8K Cr
P/E225.0
Updated25 Aug 2026
Read4 min read

What the Q1 FY27 call signalled

3 of 4 strong

RevenueModerate growth
MarginMargins up
CapexCapex planned
FundraiseFundraise planned

The short version

Confident in delivering mid-teens revenue growth from existing centers and new greenfield and brownfield expansions. Management targets EBITDA margins of 21%-22% in the next 2 years, progressing to 24%-25% in 4-5 years.

From Health.Global's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.

Revenue & Sales Performance

Moderate growth
  • Confident in delivering mid-teens revenue growth from existing centers and new greenfield and brownfield expansions.
  • Expect 11% year-on-year volume growth, supported by strong patient demand.
  • Planned addition of 65 beds in FY27, 520 beds in FY28 and FY29, and 230 beds in FY30 to drive capacity expansion.
  • Growth to be broad-based with increased utilization and ramp-up of new facilities like North Bangalore hospital.
  • Anticipate steady improvement in payor mix, case mix complexity, and clinical capabilities supporting revenue quality.
  • ARPP growth expected in line with inflation (~2%).
  • Strategic focus on more complex clinical work and enhanced patient experience likely to support sustainable top-line momentum.

2 more points from Health.Global's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Health.Global said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Q1 Capex incurred: Approximately INR 75 crore (INR 35 crore growth capex + INR 40 crore maintenance capex).
  • Full-year maintenance capex expected: Approximately INR 100 crore.
  • Capacity expansion plans:
  • Additional 65 beds in FY27.
  • 520 beds across FY28 and FY29, mainly through brownfield projects (~60%) for faster execution and low capex, and 3 greenfield projects in pipeline.
  • 230 beds planned in FY30.
  • Greenfield projects:
  • Two greenfield projects adding 180 beds in FY28 and FY29: One in South cluster (Whitefield), likely operational by end of FY28; another in Maharashtra, West cluster, expected later.
  • Strategic investments:
  • Increased shareholding in Vizag hospital from 51% to 85% with INR 150 crore deployment.

2 more points from Health.Global's call on capex

Create a free account to keep reading this call

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
1Health X Platform
Rev 1Mar 1
2Chandan Healthca
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 2
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Health.Global said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Key related points: - Capacity expansions planned: 65 beds in FY27, 520 beds in FY28 and FY29, and 230 beds in FY30. - Three greenfield projects are in the pipeline, with further details to be shared once finalized.

2 more points from Health.Global's call on order book

Create a free account to keep reading this call

Health.Global — Quarterly revenue & net profit

Revenue Net profit Net loss
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹652 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Health.Global's management said in earlier quarters

Others in Healthcare Services this season

  • Aatmaj Health (Q1 FY27)

    Revenue for Q1 FY 2026-27: ₹8.13 crore . Key investor presentation takeaways from Aatmaj Healthcare Ltd's Q1 FY27 investor presentation — and how it ranks again

  • Asarfi Hospital Ltd (Q1 FY27)

    Q1'FY27 consolidated revenue from operations: ₹47.5 Cr, up 32.8% YoY (vs ₹35.7 Cr in Q1'FY26) . Key investor presentation takeaways from Asarfi Hospital Ltd's Q

  • KMC Speciality (Q1 FY27)

    Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…

  • 3B Blackbio (Q1 FY27)

    Q1 2026-27 revenue from operations: ₹3,205.73 Lakh (including Coris sales of ₹862.83 Lakh) vs ₹1,996.06 Lakh in Q1 2025-26 — YoY growth approx. Key concall…

Compare:vs Apollo Hospitalsvs Max Healthcarevs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Health.Global and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Health.Global Q1 FY27 results?

Confident in delivering mid-teens revenue growth from existing centers and new greenfield and brownfield expansions. Management targets EBITDA margins of 21%-22% in the next 2 years, progressing to 24%-25% in 4-5 years.

What is Health.Global share price analysis?

Health.Global currently shows a below-average growth signal. The stock trades at a P/E of 225.0 with a market cap of ₹10,839 Cr. Investors should review the full earnings analysis for detailed insights.

Is Health.Global planning capital expenditure?

Q1 Capex incurred: Approximately INR 75 crore (INR 35 crore growth capex + INR 40 crore maintenance capex).

Keep Health.Global on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.